3.8 Article

Antivenom availability, delays and use in Australia

期刊

TOXICON-X
卷 17, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.toxcx.2022.100145

关键词

Antivenom; Venom; Snakebite; Diagnosis; Envenoming

向作者/读者索取更多资源

Antivenom is the main treatment for snake envenoming, but availability is a concern in resource poor regions. Early administration and selective use of antivenom are essential for effective treatment. Delays in antivenom administration occur both before and after hospitalization, and improving diagnosis speed and timing of administration are crucial.
Antivenom is the main treatment for snake envenoming and there are ongoing concerns about availability in resource poor regions of the world. However, effective antivenom treatment for snake envenoming requires more than improved availability of safe and efficacious antivenoms. Most importantly, antivenom must be administered as early as possible, and within 2-6 h of the bite in Australia. At the same time, it is also important that antivenom not be given to all patients indiscriminately with a suspected snakebite, because of the risk of anaphylaxis. Delays in the administration of antivenom are a significant impediment to effective antivenom treatment and can be divided into pre-hospital and in-hospital delays. These range from delays due to remoteness of snakebite, to delays in diagnosis and administration of antivenom once in hospital. In Australia, antivenom is readily available in most hospitals, and a large portion of patients present to hospital within 2 h of the bite. However, there is on average a further delay of 2.5 h before antivenom is administered. Early diagnosis with accurate bedside tests and rapid clinical assessment of patients with snakebite are key to improving the effective use of antivenom.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据